Citius Pharmaceuticals, Inc. (CTXR)

US — Healthcare Sector
Peers: ASRT  ATOS  GRTX  HOOK  HRTX  OTLK  PLX  SENS  TNXP  TRAW 

Automate Your Wheel Strategy on CTXR

With Tiblio's Option Bot, you can configure your own wheel strategy including CTXR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CTXR
  • Rev/Share 0.0135
  • Book/Share 5.4852
  • PB 0.2618
  • Debt/Equity 0.0154
  • CurrentRatio 0.3684
  • ROIC -0.4506

 

  • MktCap 15309065.0
  • FreeCF/Share -2.3115
  • PFCF -0.5714
  • PE -0.3724
  • Debt/Assets 0.0077
  • DivYield 0
  • ROE -0.6052

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 3
  • P/B Score 5
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade CTXR D. Boral Capital Hold Buy -- $9 Dec. 30, 2024

News

Citius Oncology Announces Pricing of $9.0 Million Public Offering
CTOR, CTXR
Published: July 16, 2025 by: PRNewsWire
Sentiment: Neutral

CRANFORD, N.J. , July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the pricing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share.

Read More
image for news Citius Oncology Announces Pricing of $9.0 Million Public Offering
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
CTOR, CTXR
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral

CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024.

Read More
image for news Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

About Citius Pharmaceuticals, Inc. (CTXR)

  • IPO Date 2014-10-02
  • Website https://www.citiuspharma.com
  • Industry Biotechnology
  • CEO Leonard L. Mazur
  • Employees 23
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.